| __timestamp | HUTCHMED (China) Limited | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 25434000 |
| Thursday, January 1, 2015 | 110777000 | 23783000 |
| Friday, January 1, 2016 | 156328000 | 29763000 |
| Sunday, January 1, 2017 | 175820000 | 12065000 |
| Monday, January 1, 2018 | 143944000 | 5508000 |
| Tuesday, January 1, 2019 | 160152000 | 75173000 |
| Wednesday, January 1, 2020 | 188519000 | 81497000 |
| Friday, January 1, 2021 | 258234000 | 85731000 |
| Saturday, January 1, 2022 | 311103000 | 63572000 |
| Sunday, January 1, 2023 | 384447000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is pivotal. Over the past decade, HUTCHMED (China) Limited and Mesoblast Limited have showcased intriguing trends in their cost of revenue. From 2014 to 2023, HUTCHMED's expenses surged by over 430%, peaking in 2023. This growth reflects their aggressive expansion and investment in R&D. In contrast, Mesoblast's costs have been more volatile, with a notable spike in 2019 and 2020, followed by a decline. By 2023, their costs had decreased by approximately 36% from their 2020 peak. This divergence highlights differing strategic approaches: HUTCHMED's consistent growth versus Mesoblast's fluctuating expenditures. As we look to 2024, with some data missing, the financial strategies of these companies will be crucial in shaping their future trajectories.
Bristol-Myers Squibb Company vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and HUTCHMED (China) Limited
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Evotec SE
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.